Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial
Abstract Background Bronchopulmonary dysplasia (BPD) is still a common complication in very premature infants. At present, there is no effective treatment for BPD. Glucocorticoids are drugs commonly used to prevent or treat BPD before and after birth. In very premature infants with high risk factors...
Main Authors: | Yuan He, Yong Zhang, Shuqiang Gao, Xiaoling Wang, Na He, Deshuang Zhang, Wenbin Dong, Christian Wieg, Xiaoping Lei |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-09-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-020-04698-0 |
Similar Items
-
Systemic Hydrocortisone To Prevent Bronchopulmonary Dysplasia in preterm infants (the SToP-BPD study): statistical analysis plan
by: Wes Onland, et al.
Published: (2018-03-01) -
MORPHOLOGICAL EVOLUTION AND DIAGNOSIS OF BRONCHOPULMONARY DYSPLASIA IN VERY PRETERM INFANTS
by: А. Меньшикова, et al.
Published: (2023-02-01) -
Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants
by: Tobias Muehlbacher, et al.
Published: (2021-04-01) -
Risk factors that affect the degree of bronchopulmonary dysplasia in very preterm infants: a 5-year retrospective study
by: Tingting Yang, et al.
Published: (2022-04-01) -
Machine learning for prediction of bronchopulmonary dysplasia-free survival among very preterm infants
by: Rebekah M. Leigh, et al.
Published: (2022-09-01)